- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
- Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
- Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
- Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
- Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
- Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
- Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
- Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
More ▼
Key statistics
On Friday, Ceapro Inc (CZO:CVE) closed at 0.26, 73.33% above the 52 week low of 0.150 set on Feb 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.245 |
---|---|
High | 0.26 |
Low | 0.24 |
Bid | 0.25 |
Offer | 0.26 |
Previous close | 0.24 |
Average volume | 19.82k |
---|---|
Shares outstanding | 78.29m |
Free float | 75.16m |
P/E (TTM) | -- |
Market cap | 20.36m CAD |
EPS (TTM) | -0.0345 CAD |
Data delayed at least 15 minutes, as of Apr 26 2024 20:08 BST.
More ▼